Literature DB >> 21328099

Morbidity and mortality on chronic haemodialysis: a 10-year Swiss single centre analysis.

Tobias Breidthardt1, Cora Nina Moser-Bucher, Claudia Praehauser, Daniela Garzoni, Katrin Bächler, Juerg Steiger, Michael Dickenmann, Michael Mayr.   

Abstract

BACKGROUND: Patient survival on chronic haemodialysis varies considerably among different countries and healthcare systems. To date, the survival of Swiss dialysis patients has not been analysed separately.
METHODS: We consecutively enrolled 266 patients entering the chronic haemodialysis program of the University Hospital Basel between 01.01.1995 and 30.06.2006 into a cohort study. Patient survival on chronic haemodialysis was the primary endpoint. Pre-specified sub-group analyses were performed for female and diabetic patients.
RESULTS: Patient age ranged from 15 to 90 years. Seventy-two percent suffered either from coronary artery, peripheral artery or cerebrovascular disease and 34% from diabetes. Sixty-nine (26%) patients underwent kidney transplantation. Transplanted patients were significantly younger (p <0.01) and less likely to suffer from diabetes (p <0.01) and atherosclerotic diseases (coronary, peripheral, cerebrovascular p for all ≤0.01). Median survival was 4.25 years (95%CI 3.66-5.50), with one, three and five year survival rates reaching 88%, 68% and 46%. Survival rates were equal in men and women (p = 0.34), among diabetic and non-diabetic patients (p = 0.41) and among men and women stratified for the presence of diabetes (p = 0.13). Overall, 34% (91/266) patients died during the observational period. Thirty three percent of all deaths were caused by cardiac events, followed by malignant diseases (8%) and infections (7%). In 9% (23/266) dialysis was withdrawn and withdrawal of dialysis contributed to death in 25% (23/91).
CONCLUSION: Survival on chronic haemodialysis treatment in Switzerland compares favourably to international reference values. Dialysis withdrawal and the frequency of kidney transplantation impact long term patient outcome and should be adjusted for when comparing mortality analysis.

Entities:  

Mesh:

Year:  2011        PMID: 21328099     DOI: 10.4414/smw.2011.13150

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  6 in total

Review 1.  Acute kidney injury in acute on chronic liver failure.

Authors:  Rakhi Maiwall; S K Sarin; Richard Moreau
Journal:  Hepatol Int       Date:  2015-10-15       Impact factor: 6.047

2.  Troponin T for the detection of dialysis-induced myocardial stunning in hemodialysis patients.

Authors:  Tobias Breidthardt; James O Burton; Aghogho Odudu; Mohamed Tarek Eldehni; Helen J Jefferies; Christopher W McIntyre
Journal:  Clin J Am Soc Nephrol       Date:  2012-07-19       Impact factor: 8.237

3.  Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients.

Authors:  Achuthan Sourianarayanane; Rupesh Raina; Gaurav Garg; Arthur J McCullough; Robert S O'Shea
Journal:  Int Urol Nephrol       Date:  2013-08-10       Impact factor: 2.370

4.  Epidemiologic trends in chronic renal replacement therapy over forty years: a Swiss dialysis experience.

Authors:  Petra Rhyn Lehmann; Manon Ambühl; Domenica Corleto; Richard Klaghofer; Patrice M Ambühl
Journal:  BMC Nephrol       Date:  2012-07-02       Impact factor: 2.388

5.  The outcome of the primary vascular access and its translation into prevalent access use rates in chronic haemodialysis patients.

Authors:  Claudia Praehauser; Tobias Breidthardt; Cora Nina Moser-Bucher; Thomas Wolff; Katrin Baechler; Thomas Eugster; Michael Dickenmann; Lorenz Gurke; Michael Mayr
Journal:  Clin Kidney J       Date:  2012-06-28

6.  Chronic Kidney Disease Induced Intestinal Mucosal Barrier Damage Associated with Intestinal Oxidative Stress Injury.

Authors:  Chao Yu; Zhen Wang; Shanjun Tan; Qiang Wang; Chunyu Zhou; Xin Kang; Shuang Zhao; Shuai Liu; Huijun Fu; Zhen Yu; Ai Peng
Journal:  Gastroenterol Res Pract       Date:  2016-07-14       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.